One year in review 2020: fibromyalgia

  • Clin Exp Rheumatol. 2020 Jan-Feb;38 Suppl 123(1):3-8.
Laura Bazzichi  1 ,  Camillo Giacomelli  2 ,  Arianna Consensi  2 ,  Valeria Giorgi  3 ,  Alberto Batticciotto  4 ,  Manuela Di Franco  5 ,  Piercarlo Sarzi-Puttini  3
Affiliations
  • 1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. [email protected].
  • 2. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • 3. Rheumatology Unit, ASST-Fatebenefratelli L. Sacco University Hospital, Milano, Italy.
  • 4. Rheumatology Unit, Internal Medicine Department, ASST Settelaghi, Ospedale Di Circolo - Fondazione Macchi, Varese, Italy.
  • 5. Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy.
PMID: 32116216
Abstract

Fibromyalgia (FM) is a frequently encountered syndrome that is characterised by chronic widespread pain, fatigue, sleep disturbances, and many Other symptoms that impair the quality of life. Its aetiopathogenesis is still unclear but, although there is no specific therapy, a number of pharmacological and non-pharmacological therapies are available. The aim of this review is to describe the most recent findings concerning the diagnosis, aetiopathogenesis and treatment of FM published between January 2019 and January 2020. They include the new concept of nociplastic pain, some neuroendocrine and metabolic alterations found in FM patients, and investigations concerning not only novel applications of old drugs, but also, and in particular, complementary therapies, such as the hyperbaric oxygen chamber, ozone therapy and mindfulness-based interventions.